Navigation Links
Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance
Date:12/14/2007

New tool for planning proton treatments makes it possible to precisely

control how dose is distributed inside the patient's body

PALO ALTO, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) has received FDA 510(k) clearance for a new proton scanning dose algorithm that offers clinicians greater control over how proton beams are used to target tumors and other abnormalities. The new algorithm, which has been incorporated into Varian's Eclipse(TM) treatment planning software, makes it possible to plan for intensity modulated proton therapy by optimizing dose distributions in three dimensions in order to protect surrounding healthy tissues.

This proton scanning technique improves on current proton delivery methods that require a therapist to enter and exit the treatment room numerous times throughout a treatment to adjust physical compensators for processing proton beams. "With proton scanning and intensity-modulation, this cumbersome process can be completely eliminated," said Jeff Amacker, Varian's business manager for treatment planning products.

PROTON THERAPY

Proton therapy uses a particle accelerator to generate a beam of protons and deposit them accurately within tumors while sparing adjacent healthy tissues and organs. Unlike the more common photon radiotherapy, with beams that pass all the way through the patient's body, proton therapy beams can be designed to stop and distribute most of their radiation dose at the depth of the tumor. This makes it possible to improve certain cancer treatments by protecting more healthy tissue and thus reduce short- and long-term side effects in cases where surrounding healthy tissues are particularly sensitive to radiation. Radiation o
'/>"/>

SOURCE Varian Medical Systems
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
2. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
3. Loma Linda University to Dedicate Proton Treatment Center to Cancer Therapy Pioneer James M. Slater, M.D.
4. Purdue researchers develop technology to detect cancer by scanning surface veins
5. Algorithms to reanimate the heart
6. Carnegie Mellon algorithm identifies top 100 blogs for news
7. Cranberry Could Juice Up Ovarian Cancer Treatment
8. New Ovarian Cancer Drug Trial Under Way
9. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
10. Pelvic Exams Can Help Spot Ovarian Cancer
11. Study fuels debate over whether exercise and body size influence ovarian cancer risk

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...Constraint-induced movement therapy (CIMT) is a po...ren with hemiplegic cerebral palsy, but more resea...w published in the November issue of Physical The...n Physical Therapy Association (APTA). The review,...ematic reviews, concluded that further research sh...
(Date:12/2/2009)... Revolutionary new cell phones that direct ...l be available in early 2010 from Aerius Internati...mber 2, 2009 -- Revolutionary new cell phones that...sers will be available in early 2010 from Aerius I...red with a Green Technology Award in wireless comm...
(Date:12/2/2009)... A team of Kendall Hunt authors earned the ...d at the recent National Association for Gifted Ch...ember 5-7, 2009. , Dubuqu...l Hunt authors earned the 2009 Gifted Child Quarte... Association for Gifted Children’s annual co...
(Date:12/2/2009)...HINGTON, Dec. 2 Pro-abo..., December 2 in their campaign against the U.S. Ho... Americans United for Life President and CEO Charm...the abortion lobby,s effort to expand taxpayer fun...h health care, the feminist groups and the abortio...
(Date:12/2/2009)...S ANGELES, Dec. 2 At a ...Tourism ministerial delegates came together to out...equired to give it the necessary thrust. Organized...edicaltourismassociation.com , the high-powered co...iscussed the opportunities and requests for assist...
Breaking Medicine News(10 mins):Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 3
...A hospital in Chennai has created history by succe...ant in an eight-year-old Ugandan boy using the co...on of what the procedure would cost internationall...ht to the Apollo Specialty Hospital here. ...
...Three gene variants in the DNA of 486 AIDS patient...the HIV virus, according to research published Th... will lead to a vaccine that would boost the prote...mising, the scientists said in a study to appear i...
...A British woman will be aiming to raise awareness ...y when she sets out on a solo row across the Pacif...Roz Savage, 38, has already traversed the Atlantic... across the vast expanse of the Pacific. S...
...Madrid is the culinary melting pot of a country wh...rld by the New York Times, the author of a new boo...here is no real Madrid cooking but that's because ...novative cooking in Madrid). Rincon came u...
...Supermodel Petra Nemcova turned vegetarian to help...gave up meat and dairy products in February after ... "I read that if we fish the way we fish, ... star insisted that that she felt a 'strong connec...
...Burlesque star Dita Von Teese says that she often ... healthy hobby to be a voyeur. The estran...ur pornography has something to offer to almost ev... She insists that she is just like other people ...
Other Medicine News:Health News:Chennai Hospital Conducts Bone Marrow Transplantation Successfully 2Health News:Three Gene Variants Could Hold Key for HIV Vaccine: Study 2Health News:Briton Set for Pacific Solo Odyssey to Highlight Warming 2
(Date:12/2/2009)... , PLEASANTON, Calif., Dec. 2 /PRNewswire-Firs...nced today that the United States Food & Drug ...ed use for its licensed nucleic acid test, to scre...dividual donations. The test, called the cobas... system, is a qualitative, in-vitro test for the s...
(Date:12/2/2009)... , NANJING, China, Dec. 2 /PRNewswire-...r the "Company") (NYSE: SCR ), a leading pharmac...anufacturing, and marketing of branded,generic and...ted that its,subsidiary Jiangsu Yanshen Biological...s suspended production of all its products in orde...
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 /PRNewsw...cluding a late-breaking presentation on Tasigna...ic myeloid leukemia, demonstrate the strength of t... care of patients. ,, The new data, at the 51s...ing and Exposition, highlight the company,s curren...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 1Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 2Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 3Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 1Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 2
...nces announced,today, the initiation of a Phase 2 ...he treatment and management of acute infectious,mo...apeutics for the,treatment for this debilitating c...n-Barr virus (EBV), "Valomaciclovir has shown a b...ibition of viral replication of herpes zoster and ...
...gel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today a... PFE ), has begun a Phase 1 clinical trial of an,...kinase inhibitor, R343,for the treatment of allerg...Rigel,s clinical portfolio., Under the terms of t...will receive a $5 million milestone payment from P...
Other Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
Alloclassic Hip
Perfecta RS Stems
S-ROM Femoral Stems - XX-Long Length Stems 36mm Neck with 21mm Calcar Replacement + Lat Neck
S-ROM Femoral Stems - Long Length Stems Standard 36mm Neck
Medicine Products: